A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis. Background: Mucin 1 (MUC1) is a tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results